Objective: High-mobility group box-1 (HMGB1) is a potent inflammatory mediator and contributes to acute lung injury in adults. The role of HMGB1 in neonatal lung injury and the development of bronchopulmonary dysplasia (BPD) is unknown. We studied the association between HMGB1 levels in tracheal aspirates (TAs) and adverse outcomes (BPD/death) in ventilated premature infants (VPIs) and modulation of HMGB1 levels with dexamethasone (Dex) use.
Introduction
Bronchopulmonary dysplasia (BPD) is the leading cause of chronic lung disease in infancy. 1 In context of the increased rate of prematurity, 2 the burden of BPD is expected to increase with the consequences of this disease extending well into adulthood. 1 Despite decades of research, the incidence of BPD has not changed significantly. 3 The pathogenesis of BPD is multifactorial, with genetic and environmental factors being intricately involved in this process. 1 Among the environmental factors, sepsis (antenatal and/ or postnatal), ventilator-induced lung injury and hyperoxia have been implicated. 1 These factors (among others) have been shown to instigate a cascade of inflammatory cytokines that can lead to tissue injury and cell death. 1 High-mobility group box-1 (HMGB1) is an abundant architectural chromosomal protein. 4 It has been shown to be an important mediator of sepsis. 5 Studies have described that HMGB1 also acts as a cytokine and mediates accumulation of neutrophils, interstitial edema and protein exudation into the alveolar space, following intratracheal administration in animal models. 5 It has been reported as a possible contributor to ventilator-induced lung injury. 6, 7 Furthermore, HMGB1 can be released from necrotic cells and cause further tissue damage. 4, 5 HMGB1 has also been shown to activate nuclear factor-kappa B (NF-kB). 4 Earlier reports have suggested the involvement of NF-kB in BPD, 8, 9 and necrotic cell death is an important consequence of hyperoxia-induced lung injury, 10 in addition to sepsis 5 and ventilator-induced lung injury. 11 The role of HMGB1 in neonatal lung injury and the development of BPD in premature infants are not known. Hence, we hypothesized that HMGB1 has an important role in the pathogenesis of BPD. Our objective in this study was to measure HMGB1 in tracheal aspirate (TA) samples in a cohort of ventilated premature infants (VPIs) and evaluate the association of HMGB1 with the development of BPD or death. In addition, we wanted to evaluate the effect of dexamethasone (Dex) use on HMGB1 levels.
Methods

Study population
The study was conducted in a 39-bed, level III neonatal intensive care unit at the Cooper University Hospital in Camden, NJ, between March 2003 and September 2008. The Institutional Review Committee approved the study, and parents signed a written informed consent. Infants born before 32 weeks gestation and requiring mechanical ventilatory support were eligible for participation. Relevant clinical data including the infant's demographics, clinical parameters, and data on respiratory support were collected from the patient's chart. BPD was defined as the need for supplemental oxygen at 36 weeks postmenstrual age (PMA).
Sample collection
The TA samples were collected on days 1, 3, 5 and 7 while the infants were mechanically ventilated. Additional TA samples were collected before and 48 to 72 h after starting steroids. The decision to treat an infant with steroids was made by an attending neonatologist taking care of the baby. Infants received a 9-day weaning course of Dex (0.3 mg kg -1 day -1 for 3 days, 0.2 mg kg -1 day -1 for 3 days and 0.1 mg -1 kg -1 day for 3 days). TA samples were obtained by instilling 0.5 ml of normal saline into the infant's endotracheal tube (ET) and suctioning the residue with a 5F suction catheter after two or three ventilator breaths. The suction catheter was passed to a standardized length of 0.5 to 1 cm beyond the tip of the ET tube. This method of collection is used widely in neonates to collect TA samples, 10 and it is well tolerated by even the most critically ill neonates. The procedure was repeated three times and replicates were pooled. The suction catheter was flushed with 0.5 ml of normal saline after each suctioning episode to collect the residual sample in the catheter. The samples were immediately transported on ice and processed within 30 min in the laboratory. The samples were centrifuged at 4 1C for 10 min at 300 g. The supernatant was collected, divided into aliquots and stored at À70 1C for future use.
HMGB1 assay
The level of HMGB1 was measured using commercially available enzyme-linked immunosorbent assay (ELISA) kit (Shino-test, Kanagawa, Japan) according to manufacturer's instructions. The sensitivity of this assay was 1 ng ml -1 with a dynamic range between 2.5 and 80 ng ml -1 .
Protein assay
Total protein concentration was measured in each TA sample using Bradford assay (Bio-Rad, Richmond, CA, USA) to correct for dilution during the lavage procedure. The level of HMGB1 was expressed as pg mg -1 of protein.
Statistical analyses
Statistics were performed using Sigma Stat 3.1 for Windows statistical package (Systat Software, Point Richmond, CA, USA).
Comparisons between groups were carried out using Student's t-test and Mann-Whitney rank sum test for continuous data and w 2 or Fisher's exact test for categorical data. Stepwise logistic regression analysis was performed to adjust for difference in birth weight between the two groups. Two-way repeated measures analyses of variance were performed on log-transformed data. Receiver operating characteristic curve analysis was performed using MedCalc (Broekstraat, Belgium) statistical software. The difference was considered significant at P<0.05.
Results
A total of 235 TA samples were collected from 84 VPIs (mean ± s.d.: birth weight 780 ± 183 g, gestational age 25.7 ± 1.6 weeks) during the first week of life. Additional 58 TA samples were collected from 29 infants who received steroids. HMGB1 was detectable in all TA samples. The median HMGB1 level of all aspirates was 14.2 ng ml -1 (range 1.2 to 121.5 ng ml -1 ).
BPD, mortality and HMGB1
In all, 24 infants had no BPD, 42 infants developed BPD and 18 infants died before 36 weeks PMA. Clinical characteristics of the two groups are summarized in Table 1 . Birth weight and gestational age were higher in infants with no BPD compared with infants who developed BPD or died. The duration of mechanical ventilation, oxygen therapy and hospitalization was also lower in infants with no BPD. However, there was no significant difference in other demographics between the two groups. Similarly, there , P ¼ 0.004) (Figure 1) . The HMGB1 levels were also compared between the groups without correcting for dilution (levels expressed as ng ml In a logistic regression model after adjusting for birth weight, the mean HMGB1 level from first week of life was found to be an independent predictor of BPD or death (odds ratio 1.039, 95% confidence interval 1.009 to 1.070, P ¼ 0.01).
The level of HMGB1 was compared at each time point (days 1, 3, 5 and 7) in infants with no BPD and infants who developed BPD or died. Using a two-way repeated measures analysis of variance on log-transformed data, there was a significant difference between no-BPD and BPD or died groups (P ¼ 0.005). The HMGB1 level was significantly lower on days 1 (P ¼ 0.03) and 3 (P ¼ 0.039), and there was a trend toward lower levels on day 7 (P ¼ 0.076) in the no-BPD group (Figure 2 ).
The cutoff HMGB1 value with the highest accuracy was found to be 30.83 ng mg -1 , with a sensitivity and specificity of 75 and 75%, respectively, and a positive predictive value (PPV) and a negative predictive value (NPV) of 86 and 60%, respectively, on day 1. On day 7, the HMGB1 level of 23.92 ng mg -1 had a sensitivity and specificity of 72 and 69%, and PPV and NPV of 90 and 41%, respectively. Receiver operating characteristic curves for values on day 1, day 7 and averaged over the first postnatal week are shown in Figure 3 .
Dex and HMGB1
A total of 29 premature neonates (mean±s.d.: birth weight 730 ± 133 g, gestational age 25.3 ± 1.4 weeks) received Dex. The median age of starting steroids was 23 days (range 13 to 60 days). There was no significant change in HMGB1 levels with steroid therapy (before 47.0 ± 43.9 ng mg -1 , after 60.1. ± 58.8 ng mg -1 ,
Discussion
This study has two major observations. First, we report that increased TA HMGB1 levels are sustained over the first postnatal week in VPIs who develop BPD and/or died. Second, Dex therapy does not alter HMGB1 TA levels.
High-mobility group box-1, which has been previously known as a transcriptional regulation factor, 5,11 was unexpectedly Figure 1 The level of high-mobility group box-1 (HMGB1) (ng per mg of protein) in tracheal aspirates from infants with no bronchopulmonary dysplasia (BPD) (n ¼ 24), with BPD (n ¼ 42) and from those who developed BPD or died before 36 weeks postmenstrual age (PMA) (n ¼ 60). The level was significantly higher in infants who developed BPD compared with those who did not develop (P ¼ 0.002 by Mann-Whitney rank sum test). The level was also significantly higher in infants who developed BPD or died before 36 weeks PMA compared with those who did not develop BPD (P ¼ 0.004 by Mann-Whitney rank sum test). Box plot: the boundary of the box indicates the 25th and 75th percentiles, the line within the box marks the median value, and the error bars indicate the 5th and 95th percentiles.
identified as a late mediator of endotoxin-induced lethality.
12
HMGB1 can be released actively by innate immune cells (macrophages, monocytes) or passively by necrotic cells. 5 Active release of HMGB1 has been shown to be mediated by endotoxin or by proinflammatory cytokines, such as tumor necrosis factor-alpha (TNF-a) and interleukin-1beta (IL-1b).
5 HMGB1 has also been implicated as a late-acting mediator in adult animal models of ventilator-induced 6,13 and hyperoxia-induced lung injury.
14 Figure 2 The level of high-mobility group box-1 (HMGB1) on days 1, 3, 5 and 7 in infants with no bronchopulmonary dysplasia (BPD) and BPD or died before 36 weeks postmenstrual age (PMA). The HMGB1 level was significantly higher on day 1 (P ¼ 0.03 by analysis of variance, ANOVA) and day 3 (P ¼ 0.039 by ANOVA), and there was a trend toward higher level on day 7 (P ¼ 0.076 by ANOVA) in infants who developed BPD or died before 36 weeks PMA. Box plot: the boundary of the box indicates the 25th and 75th percentiles, the line within the box marks the median value, and the error bars indicate the 5th and 95th percentiles. Figure 3 Receiver operating characteristic (ROC) curves of high-mobility group box-1 (HMGB1) values on day 1, day 7 and averaged over days 1 to 7, as a predictor of bronchopulmonary dysplasia/death.
Moreover, HMGB1 has been found to be increased in bronchoalveolar lavage fluid obtained from mechanically ventilated adult patients and those with sepsis/ventilator-associated pneumonia. 13, 15 Sepsis, 16 ventilator-17 and hyperoxia-induced 18 lung injury are all known to lead to necrotic cell deathFanother potential source of HMGB1.
In the pathogenesis of BPD, all three of the above listed factors (antenatal/postnatal sepsis, ventilator-induced trauma and hyperoxia exposure) have been postulated as key players in the initiation of the cytokine-induced inflammatory cascade that ultimately culminates in BPD. 1 A recent report has implicated HMGB1 in an animal model of chorioamnionitis. 19 Interestingly, both TNF-a and IL-1b, known to be early-release cytokines in response to injurious stimuli and potent inducers of the late-release cytokine HMGB1, have been implicated in animal models 20, 21 and human 22 BPD. Although we were unable to locate any reports of HMGB1 in developmentally appropriate animal models of BPD, HMGB1 has been reported to mediate the inflammatory cascade in an experimental model of necrotizing enterocolitis in neonatal rats. 23 Recently, elevated serum HMGB1 concentrations were noted in a cohort of asphyxiated neonates. 24 As inflammatory cytokines, as alluded to above, are involved in the pathogenesis of BPD, our data on HMGB1 TA concentrations would be a biologically plausible association.
Dexamethasone has been shown to decrease the release of TNFa and IL-1b in various tissues in response to endotoxin stimulation. 25 In addition, HMGB1 has been shown to act through NF-kB, 4, 26 glucocorticoids are known to inhibit the NF-kB signaling system, 27 and Dex has been shown to suppress NF-kB expression in TA cells obtained from VPI. 28 Hence, we had expected to observe a decrease in HMGB1 levels in response to Dex treatment. This, however, did not turn out to be true. In support of our observation, Dex administration (up to suprapharmacological concentrations) to endotoxin-stimulated murine macrophage-like RAW 264.7 cells failed to decrease HMGB1 levels, although it effectively attenuated TNF secretion. 29 As one would similarly anticipate suppression of the inflammatory cytokines (TNF-a and IL-1) in infants given systemic Dex, 30, 31 we speculate that the major source of HMGB1 release at this juncture is perhaps from necrotic cells in the airway/lung. As the turnover of HMGB1 is slow, it is possible that we measured its level very soon after starting steroids. However, it has been recently reported that HMGB1 level was increased immediately after birth in asphyxiated infants, 24 suggesting a rapid turnover of HMGB1 in neonates.
Although one study has shown that TA specimens may be a suitable substitute for bronchoalveolar lavage samples in preterm infants, 32 there has been some controversy regarding whether the measurements of these markers in the TA need to be 'normalized' for them to be valid. Although some have advocated the use of total protein, 10,33 secretory component of IgA 34 and serum urea 1 for the same, others have espoused that no 'normalization' is required. 1 This study has reported HMGB1 values normalized to total protein to correct for dilution. However, even when the data were expressed without correcting for dilution, HMGB1 levels remained significantly elevated in babies who went on to develop BPD and/or died. A potential selection bias is another limitation of this study.
Only premature infants mechanically ventilated were enrolled. Less sick infants managed on continuous positive airway pressure were excluded. However, this is a limiting factor in all studies carried out on TA samples. The strengths of this study include the facts that a large cohort of VPI was evaluated, multiple samples were obtained at clinically relevant time points, and BPD was defined at 36 weeks PMA. Thus, this study shows the translational relevance of HMGB1 in the appropriate clinical setting. Although the biological relevance in developmentally appropriate animal models of BPD are still lacking, there is sufficient data from in vitro and in vivo testing, 5, 11 which suggest that HMGB1 may have a role in the pathogenesis of BPD.
In summary, this study has noted significantly increased TA HMGB1 levels in VPI who go on to develop BPD and/or die. We hope our results will be an impetus to investigating the possible role of HMGB1 in the pathogenesis as well as a potential diagnostic and/or therapeutic target 35 to ameliorate BPD.
